Biotech Acquisition Company
BIOT
NASDAQ Capital Market10.15
USD
-0.08
- -
CIK
0001825413
ISIN
KYG1125A1085
CUSIP
G1125A108
Return %
Stock
S&P500
1Y
3.26
26.53
3Y
4.64
76.60
5Y
4.64
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Michael Shleifer
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 545 West 25th Street New York City NY United States of America 10001
- IPO Date
- Mar 18, 2021
- CIK
- 0001825413
- Similar Companies
- Business
- Biotech Acquisition Company (NASDAQ: BIOT) operates as a blank check company whose sole purpose is to effect a merger, capital stock exchange, share purchase, asset acquisition, reorganization, or similar business combination with one or more businesses, primarily targeting the biotechnology sector; it currently conducts no significant operations or offers no products or services. Incorporated in 2020 and headquartered in New York, New York, the company focuses on life sciences opportunities without specified geographic operations beyond the United States. In 2022, Biotech Acquisition Company announced and later mutually terminated a proposed merger with Blade Therapeutics, Inc., a developer of therapies for fibrotic diseases, after filing a registration statement and postponing shareholder meetings amid challenging market conditions. As of late 2025, no further mergers, acquisitions, funding rounds, or strategic shifts have materialized, with the company remaining in search of a suitable target and potentially facing delisting risks.
Relativity Acquisition Corp. SPAC and Instinct Bio Technical Co. Announce Effectiveness of Registration Statement